Work

Histidine-improved cancer immunosurveillance

Year: 2026

Type: editorial

Abstract: Cancer immunotherapy has transformed clinical oncology, yet durable responses to immune checkpoint inhibitors (ICI) remain restricted to a minority of patients. Although genomic and immunological d...

Source: OncoImmunology

DOI: 10.1080/2162402x.2026.2713805

Authors: Marine Fidelle, Ella Reich, Laurence Zitvogel, Guido Kroemer

Institutions: Inserm, Université Paris-Saclay, Université Paris Cité, Institut Gustave Roussy, Sorbonne Université, Centre de Recherche des Cordeliers, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913

Funders: Seerave Foundation, Agence Nationale de la Recherche, Fondation ARC pour la Recherche sur le Cancer, Ligue Contre le Cancer, Institut Universitaire de France, Institut National Du Cancer, Horizon 2020 Framework Programme, HORIZON EUROPE Framework Programme, European Research Council

Awards: G1131470905, Next-generation phenotypic screening for oncological applications, G4406617139, G6318841463, G8401059989, Université de Paris, G92820738

OpenAlex ID: W7203499412

Cites: 13

Cited by:

Related to: 10